PE20091086A1 - Compuestos que potencian el receptor de ampa y usos de los mismos en medicina - Google Patents

Compuestos que potencian el receptor de ampa y usos de los mismos en medicina

Info

Publication number
PE20091086A1
PE20091086A1 PE2008002104A PE2008002104A PE20091086A1 PE 20091086 A1 PE20091086 A1 PE 20091086A1 PE 2008002104 A PE2008002104 A PE 2008002104A PE 2008002104 A PE2008002104 A PE 2008002104A PE 20091086 A1 PE20091086 A1 PE 20091086A1
Authority
PE
Peru
Prior art keywords
compounds
propanosulfonamide
inden
dihydro
medicine
Prior art date
Application number
PE2008002104A
Other languages
English (en)
Inventor
Nicolas Bertheleme
Wai Ngor Chan
Jaqueline Sandra Scott
Simon Edward Ward
Simon E Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0724783A external-priority patent/GB0724783D0/en
Priority claimed from GB0818068A external-priority patent/GB0818068D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20091086A1 publication Critical patent/PE20091086A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • C07D213/6432-Phenoxypyridines; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2,3-DIHIDRO-1H-INDEN-2-PROPANOSULFONAMIDA DE FORMULA (I) DONDE n ES DE 0 A 3; R1 ES FENILO O PIRIDILO OPCIONALMENTE SUSTITUIDOS CON ALQUILO(C1-C4) Y HALOGENO; R2 ES H O CH3 CUANDO n ES 1 Y R2 ES H CUANDO n ES DE 2 O 3. SON COMPUESTOS PREFERIDOS: N-[(2S)-5-(FENILOXI)-2,3-DIHIDRO-1H-INDEN-2-IL]-2-PROPANOSULFONAMIDA, N-{(2S)-5-[(6-METIL-3-PIRIDINIL)OXI]-2,3-DIHIDRO-1H-INDEN-2-IL}-2-PROPANOSULFONAMIDA, N-[(2S)-5-(2-PIRIDINILOXI)-2,3-DIHIDRO-1H-INDEN-2-IL]-2-PROPANOSULFONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON POTENCIADORES DEL RECEPTOR a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) SIENDO UTILES EN EL TRATAMIENTO DE DEPRESION, TRASTORNOS DE ANSIEDAD, ESQUIZOFRENIA
PE2008002104A 2007-12-19 2008-12-17 Compuestos que potencian el receptor de ampa y usos de los mismos en medicina PE20091086A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0724783A GB0724783D0 (en) 2007-12-19 2007-12-19 Compounds
GB0818068A GB0818068D0 (en) 2008-10-02 2008-10-02 Compounds

Publications (1)

Publication Number Publication Date
PE20091086A1 true PE20091086A1 (es) 2009-08-23

Family

ID=40566351

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002104A PE20091086A1 (es) 2007-12-19 2008-12-17 Compuestos que potencian el receptor de ampa y usos de los mismos en medicina

Country Status (9)

Country Link
US (1) US8173820B2 (es)
EP (1) EP2222632A1 (es)
JP (1) JP2011506551A (es)
AR (1) AR069781A1 (es)
CL (1) CL2008003773A1 (es)
PE (1) PE20091086A1 (es)
TW (1) TW200940491A (es)
UY (1) UY31544A1 (es)
WO (1) WO2009080637A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
TW201012803A (en) * 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
GB0821166D0 (en) * 2008-11-19 2008-12-24 Glaxo Group Ltd Compounds
US8633237B2 (en) 2009-04-09 2014-01-21 Merck Sharp & Dohme B.V. Indane derivatives
US9527807B2 (en) 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
JP6319805B2 (ja) * 2014-10-08 2018-05-09 田岡化学工業株式会社 スピロビフルオレン骨格を有するジオール化合物およびその製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006537A1 (en) * 1998-07-31 2000-02-10 Eli Lilly And Company N-substituted sulfonamide derivatives
GB0417709D0 (en) * 2004-08-09 2004-09-08 Glaxo Group Ltd Compounds
EP1781614B1 (en) 2004-08-09 2009-06-24 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine

Also Published As

Publication number Publication date
JP2011506551A (ja) 2011-03-03
US20110021578A1 (en) 2011-01-27
WO2009080637A1 (en) 2009-07-02
US8173820B2 (en) 2012-05-08
EP2222632A1 (en) 2010-09-01
TW200940491A (en) 2009-10-01
CL2008003773A1 (es) 2010-03-05
UY31544A1 (es) 2009-07-17
AR069781A1 (es) 2010-02-17

Similar Documents

Publication Publication Date Title
PE20091086A1 (es) Compuestos que potencian el receptor de ampa y usos de los mismos en medicina
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20190806A1 (es) Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
PE20081532A1 (es) Compuestos novedosos
PE20161400A1 (es) Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
AR064452A1 (es) Derivados de 1,2,4 oxadiazol-indol,composiciones farmaceuticas que los comprenden y usos en trastornos asociados a receptores s1p1.
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20091425A1 (es) Derivados de aminotiazol
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
PE20141375A1 (es) Activadores de glucoquinasa
AR060651A1 (es) Derivados de 1,2,4-triazol como moduladores de mglur5 i, intermediarios para su sintesis, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del dolor y de trastornos gastrointestinales
JP2008513516A5 (es)
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
PE20091000A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
PE20140934A1 (es) Derivados de pirazol
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
AR057869A1 (es) Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuesto
AR066020A1 (es) Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1.
PE20080927A1 (es) Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk)
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol

Legal Events

Date Code Title Description
FD Application declared void or lapsed